Gilead Sciences, Inc. (NASDAQ:GILD) Stock Position Lowered by Dearborn Partners LLC

Dearborn Partners LLC trimmed its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 71.7% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 90,401 shares of the biopharmaceutical company's stock after selling 228,724 shares during the period. Dearborn Partners LLC's holdings in Gilead Sciences were worth $8,350,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the company. FMR LLC boosted its stake in Gilead Sciences by 79.4% in the third quarter. FMR LLC now owns 33,162,319 shares of the biopharmaceutical company's stock valued at $2,780,329,000 after acquiring an additional 14,680,161 shares during the last quarter. Wellington Management Group LLP lifted its stake in shares of Gilead Sciences by 50.9% during the 3rd quarter. Wellington Management Group LLP now owns 34,600,676 shares of the biopharmaceutical company's stock valued at $2,900,921,000 after buying an additional 11,665,593 shares in the last quarter. Pacer Advisors Inc. lifted its stake in shares of Gilead Sciences by 723.3% during the 4th quarter. Pacer Advisors Inc. now owns 6,434,665 shares of the biopharmaceutical company's stock valued at $594,370,000 after buying an additional 5,653,075 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in shares of Gilead Sciences during the 4th quarter valued at approximately $207,340,000. Finally, Point72 Asset Management L.P. lifted its stake in shares of Gilead Sciences by 350.1% during the 3rd quarter. Point72 Asset Management L.P. now owns 2,305,270 shares of the biopharmaceutical company's stock valued at $193,274,000 after buying an additional 1,793,145 shares in the last quarter. 83.67% of the stock is owned by institutional investors.

Remove Ads

Gilead Sciences Stock Performance

Shares of NASDAQ:GILD traded down $2.78 during trading on Tuesday, reaching $114.43. The company had a trading volume of 11,477,486 shares, compared to its average volume of 8,252,700. The firm has a market capitalization of $142.50 billion, a price-to-earnings ratio of 309.27, a price-to-earnings-growth ratio of 0.71 and a beta of 0.21. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. The stock's fifty day moving average price is $100.56 and its 200 day moving average price is $92.18. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $119.96.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, beating analysts' consensus estimates of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. As a group, equities research analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Stockholders of record on Friday, March 14th will be issued a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.76%. This is an increase from Gilead Sciences's previous quarterly dividend of $0.77. The ex-dividend date of this dividend is Friday, March 14th. Gilead Sciences's dividend payout ratio (DPR) is 854.05%.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on GILD. Daiwa America upgraded shares of Gilead Sciences to a "hold" rating in a research note on Monday, November 18th. Bank of America increased their target price on shares of Gilead Sciences from $116.00 to $126.00 and gave the stock a "buy" rating in a research note on Wednesday, March 5th. Piper Sandler increased their target price on shares of Gilead Sciences from $105.00 to $110.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 12th. JPMorgan Chase & Co. increased their target price on shares of Gilead Sciences from $105.00 to $115.00 and gave the stock an "overweight" rating in a research note on Wednesday, January 29th. Finally, Cantor Fitzgerald reiterated a "neutral" rating and issued a $80.00 target price on shares of Gilead Sciences in a research note on Wednesday, December 11th. Eleven research analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $104.52.

Insider Transactions at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the business's stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total transaction of $228,375.00. Following the completion of the transaction, the chief financial officer now owns 129,873 shares in the company, valued at $11,863,898.55. The trade was a 1.89 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders have sold a total of 293,356 shares of company stock worth $29,166,240 in the last three months. 0.16% of the stock is currently owned by company insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.